Positive preliminary data with the T-cell receptor fusion construct, gavocabtagene autoleucel
Manageable toxicity profile and signs of clinical benefit seen with gavocabtagene autoleucel in treatment-refractory mesothelin-expressing solid tumours
Novel approaches to improve immunotherapy and more news on synthetic lethality
The ESMO Congress 2021 has started today with three sessions on developmental therapeutics, including immunotherapy. The overarching theme in these sessions is the improvement of checkpoint inhibitor-based immunotherapy and a new flavour of synthetic lethality in molecularly pre-defined solid tumours.
Women receiving immunotherapy may be at higher risk of adverse events than men
Prospective evidence from a multicentre study support the need for a more personalised immuno-oncology approach based on sex and gender differences
Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
CAR-T cell therapy in solid tumours: will we ever replicate the success rates achieved in blood cancers?
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi
The “holy grail” of lung cancer research: bring the immune system into every tumour
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
Cancer vaccination: a new era of innovation
Promising results with cancer vaccines based on specific antigen mutations in individual tumours, and typically used in combination with checkpoint inhibitors, are fuelling an upsurge of interest in cancer vaccination for patients with established cancer, explains Prof. Pedro Romero.